12:40:40 PM

CNTB Stock News

CNTB - Connect Biopharma Holdings Ltd

11/22/21 8:00 AM

Nasdaq : CNTB

managementlow float

Connect Biopharma Expands Executive Leadership Team with Hire of Chief Financial Officer

Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases

RHEA-AI

very positive

11/19/21 8:00 AM

Nasdaq : CNTB

clinical triallow float

Connect Biopharma Completes Enrollment of CBP-307 Global Phase 2 Clinical Trial in Moderate-to-Severe Ulcerative Colitis

RHEA-AI

neutral

11/18/21 4:02 PM

Nasdaq : CNTB

clinical triallow float

Connect Biopharma Reports Positive Top-Line Results from the Global Phase 2 Clinical Trial of CBP-201 in Patients with Moderate-to-Severe Atopic Dermatitis

Primary endpoint met with all three CBP-201 arms achieving significant improvements Significant improvements also reported for key secondary endpoints including other measures of skin clearance and itch with CBP-201 300mg every two weeks ( Q2W) arm The Company intends to initiate a Phase 3 trial

RHEA-AI

neutral

11/11/21 8:00 AM

Nasdaq : CNTB

conferenceslow float

Connect Biopharma to Participate at Upcoming Conferences

Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases

RHEA-AI

neutral

10/19/21 8:00 AM

Nasdaq : CNTB

conferenceslow float

Connect Biopharma to Participate at the Jefferies Virtual China Biotech Summit

RHEA-AI

neutral

09/08/21 8:00 AM

Nasdaq : CNTB

clinical triallow float

Connect Biopharma Announces First Subject Dosed in Phase 2 Trial Evaluating CBP-201 in Adult Patients with Chronic Rhinosinusitis with Nasal Polyps

RHEA-AI

neutral

09/02/21 8:00 AM

Nasdaq : CNTB

low float

Connect Biopharma Announces First Patient Dosed in China Pivotal Trial Evaluating CBP-201 in Adults with Moderate-to-Severe Atopic Dermatitis

RHEA-AI

neutral

08/31/21 4:05 PM

Nasdaq : CNTB

earningslow float

Connect Biopharma Provides Business Update and Reports First Half 2021 Financial Results

Connect Biopharma

RHEA-AI

neutral

08/25/21 8:00 AM

Nasdaq : CNTB

conferencesearningslow float

Connect Biopharma to Host First Half 2021 Financial Results Conference Call on September 1, 2021

RHEA-AI

neutral

08/23/21 4:05 PM

Nasdaq : CNTB

managementlow float

Connect Biopharma Hires General Counsel & Chief Compliance Officer and Appoints a New Board Member

RHEA-AI

very positive

1 2 Next

CNTB Data:

IndustryResearch and Development in Biotechnology
Websitewww.connectbiopharm.com
Security nameConnect Biopharma Holdings Ltd - ADR
Issue typead
SectorProfessional, Scientific, and Technical Services
Sic code2834

CNTB Description:

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from its T cell-driven research. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα), which is a validated target for the treatment of several inflammatory diseases such as atopic dermatitis (AD) and asthma. Its second lead product candidate is CBP-307, a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1 (S1P1).